The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer.
 
Milou Schuurbiers
No Relationships to Disclose
 
Christopher Gareth Smith
Employment - NeoGenomics Laboratories
 
Koen Hartemink
No Relationships to Disclose
 
Robert Rintoul
Honoraria - AstraZeneca; Inivata; Janssen; Roche
Consulting or Advisory Role - Janssen
Speakers' Bureau - Inivata; Olympus Medical Systems
Research Funding - Owlstone Medical (Inst)
Travel, Accommodations, Expenses - Owlstone Medical
 
Kim Monkhorst
Consulting or Advisory Role - Amgen; Bayer; Lilly O.
 
Daan van den Broek
Research Funding - Delfi Diagnostics
 
Nitzan Rosenfeld
Employment - Inivata; NeoGenomics Laboratories; Storm Therapeutics (I)
Leadership - Inivata
Stock and Other Ownership Interests - Mission Therapeutics (I); NeoGenomics Laboratories; Storm Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Cancer Research UK; Inivata
 
Michel van den Heuvel
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Research funding by Roche-Genentech, AstraZeneca, Pfizer, Novartis, Merck